Amgen ended its collaboration with Kyowa Kirin on the development and commercialization of rocatinlimab for atopic dermatitis following a strategic review of its portfolio.[1][3][5] The companies entered into an agreement in 2021, with Amgen paying $400 million upfront.[4][7] Rocatinlimab is an investigational monoclonal antibody drug against the OX40 receptor for the treatment of moderate to severe atopic dermatitis.[1][2][5] In the Phase 3 ROCKET-IGNITE and ROCKET-HORIZON clinical trials, rocatinlimab achieved statistically significant improvements over placebo, including EASI-75 response and vIGA-AD score of 0 or 1.[2] In the IGNITE trial, more than 40% of patients achieved at least a 75% reduction in EASI score at 24 weeks, in HORIZON 32.8%.[4] Kyowa Kirin will assume full responsibility for the program, plans to file for approval with the FDA and in Japan in the first half of the year, and continues clinical trials without interruption.[1][3][5] Amgen will continue to manufacture the drug.[1][5] Studies have shown long-term safety and sustained efficacy after one year of treatment.[4]